Esperion Expects Phase IIb Data By Year-End On Cholesterol Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
The recently public company completed Phase IIa studies for lead candidate ETC-1002 and intends to complete a pair of Phase IIb studies before year-end.
You may also be interested in...
Esperion's LDL-Cholesterol Drug To Follow PCSK9 Inhibitor Approval Pathway
Company says FDA confirmed that cardiovascular outcomes data will not be required for initial submission of ETC-1002 in patients with familial hypercholesterolemia and atherosclerotic CV disease; Esperion expects to start Phase III development by the end of 2015.
Aiming For Non-Statin Cholesterol Drug Market, Esperion Takes $33M
Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.
Pfizer Spins Off Esperion While Retaining Former Subsidiary’s Top Compounds
Pfizer retains undisclosed stake in Esperion, which will focus on small-molecule dyslipidemia candidate.